Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.56 |
| ▸ | MTOR | P42345 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179420 | 1.00 | PIK3CA (0.56) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL179421 | 1.00 | PIK3CA (0.56) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL19618136 | 0.90 | PIK3CA (0.53) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL27408140 | 0.88 | PIK3CA (0.58) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL9924586 | 0.88 | PIK3CA (0.58) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL12187039 | 0.88 | PIK3CA (0.58) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL5019512 | 0.88 | PIK3CA (0.71) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL15679247 | 0.85 | PIK3CA (0.58) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL19261367 | 0.84 | PIK3CA (0.54) | PIK3CAMTORKMT2ACDK1CCNB1 | |
| SCHEMBL244324 | 0.83 | PIK3CA (0.56) | PIK3CAMTORKMT2ACDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CA 1/4885MTOR 49/4885KMT2A 2988/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | PIK3CA 3/4885MTOR 60/4885KMT2A 2628/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CA 1/4885MTOR 104/4885KMT2A 3867/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | PIK3CA 1/4885MTOR 32/4885KMT2A 2734/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885MTOR 16/4885KMT2A 3819/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | PIK3CA 3/4885MTOR 60/4885KMT2A 2628/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CA 1/4885MTOR 49/4885KMT2A 2988/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CA 1/4885MTOR 49/4885KMT2A 2988/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CA 1/4885MTOR 104/4885KMT2A 3867/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CA 1/4885MTOR 53/4885KMT2A 3668/4885 |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CA 1/4885MTOR 104/4885KMT2A 3867/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CA 1/4885MTOR 280/4885KMT2A 985/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CA 1/4885MTOR 280/4885KMT2A 985/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885MTOR 30/4885KMT2A 3809/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | PIK3CA 1/4885MTOR 104/4885KMT2A 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.